title: Developing anti-inflammatory therapeutics for patients with osteoarthritis.
abstract: OA is the most common joint disorder in the world, but there are no approved therapeutics to prevent disease progression. Historically, OA has been considered a wear-and-tear joint disease, and efforts to identify and develop disease-modifying therapeutics have predominantly focused on direct inhibition of cartilage degeneration. However, there is now increasing evidence that inflammation is a key mediator of OA joint pathology, and also that the link between obesity and OA is not solely due to excessive load-bearing, suggesting therefore that targeting inflammation in OA could be a rewarding therapeutic strategy. In this review we therefore re-evaluate historical clinical trial data on anti-inflammatory therapeutics in OA patients, highlight some of the more promising emerging therapeutic targets and discuss the implications for future clinical trial design.
authors: Institute of Inflammation and Ageing, MRC-ARUK Centre for Musculoskeletal Ageing Research, Medical School, Queen Elizabeth Hospital, University of Birmingham.
authors: Ashleigh M
authors: AM
authors: Philp
authors: The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham.
authors: Edward T
authors: ET
authors: Davis
authors: Institute of Inflammation and Ageing, MRC-ARUK Centre for Musculoskeletal Ageing Research, Medical School, Queen Elizabeth Hospital, University of Birmingham.
authors: Simon W
authors: SW
authors: Jones
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D016718:Arachidonic Acid / Q000037:antagonists & inhibitors; D001685:Biological Factors / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D055808:Drug Discovery; D006801:Humans; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors; D020935:MAP Kinase Signaling System / Q000187:drug effects; D009569:Nitric Oxide / Q000037:antagonists & inhibitors; D010003:Osteoarthritis / Q000188:drug therapy*; D034622:RNA Interference / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D051193:Toll-Like Receptors / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D001685:Biological Factors; D016207:Cytokines; D053583:Interleukin-1beta; D051193:Toll-Like Receptors; D014409:Tumor Necrosis Factor-alpha; D016718:Arachidonic Acid; D009569:Nitric Oxide
keywords: cytokines; inflammation; osteoarthritis; synovitis; therapeutics